Clinical Trial Details

CANOPY-A USOR 17167

A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Lung Cancer
Study Type: Interventional
Phase: III
Study Start Date: 09/06/2018
Study Completion Date: 09/2025

The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

NCT Number

NCT03447769

Principal Investigator(s)

Jun F Sun, MD

Sponsor(s)

Novartis Pharmaceuticals

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female